HK Stock Market Move | MEDTIDE (03880) rose by more than 6%, with a projected year-on-year profit growth of approximately 237.8% to 288.5% in 2025.

MEDTIDE (03880) rose more than 6%, and as of the time of writing, it had risen 6.72%, reaching 26.98 Hong Kong dollars with a turnover of 1.2467 million Hong Kong dollars. In terms of news, MEDTIDE announced that the group's revenue for the year ending December 31, 2025 is expected to be approximately 5.55 billion to 5.85 billion yuan, an increase of about 25.5% to 32.3% year-on-year; and profits of about 2 billion to 2.3 billion yuan, an increase of about 237.8% to 288.5% year-on-year. MEDTIDE stated that the increase in revenue is mainly due to the successful implementation of the "follow-the-molecule" strategy, the advantages of the group's integrated contract research, development, and manufacturing organization (CRDMO) platform, industry-leading project delivery timeliness and excellent project execution performance, as well as the sustained strong demand from key customers for the company's services, due to the progress of its research and development pipeline and the rapid expansion of the global peptide market (especially in the area of glucagon-like peptide-1 (GLP-1)).